Based on a solid scientific and technical expertise as well as a strong intellectual property position, Innogenetics has developed a neurodegenerative diseases program that focuses on the creation of a panel of robust tests for the early and differential diagnosis of the primary dementias.
This market can currently be considered as embryonic. However, the added value of biomarkers in (differential) diagnosis of dementia, combined with the evaluation of a large number of disease-modifying candidate drugs in Phase I and II clinical trials ensure that Innogenetics is well-placed to become the leading theranostic player in the field of Alzheimer�|s disease testing.
The first products, such as INNOTEST� hTAU Ag, INNOTEST� �-AMYLOID(1-42), INNOTEST� PHOSPHO-TAU(181P) and INNO-LiPA ApoE are already on the market, addressing the needs of the diagnostic and therapeutic research.
